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THE POTENTIAL USE of antibody for
diagnostic or therapeutic applications in
human cancer may well depend upon the
ability to synthesize large quantities of
monospecific "anti-tumour" immuno-
globulin in vitro. In this respect, the
hybridoma technology has produced
murine monoclonal antibodies directed
against a number of human tumour-asso-
ciated antigens (Koprowski et al., 1978;
Yeh et al., 1979; Kennett & Gilbert, 1979;
Levy et al., 1979; Herlyn et al., 1979;
Accolla et al., 1980). However, the estab-
lishment of hybrid cell lines to produce
human antibodies with defined tumour
specificities has not yet been successful.
There is an alternative method for
producing human antibody in vitro by
infecting B lymphocytes with Epstein-
Barr virus (EBV) to establish human
lymphoblastoid cell lines. In 1977, Steinitz
et al. and Luzzanti et al. first reported in
vitroproductionofspecific humanantibody
on the synthetic hapten NNP (4-hydroxy-
3,5-dinitrophenacetic acid) and to hetero-
logous erythrocytes, respectively, from
EBV-transformed B lymphoblastoid cells.
Following these studies, several other
specific antibodies were produced in vitro
by EBV transformation, including those
to tetanus toxoid (Zurawski et al., 1978),
the hapten trinitrophenyl (TNP) (Kozbor
et al., 1979), the blood-group antigen Rh
(Koskimies, 1979) and to diphtheria toxin
(Tsuchiya et al., 1980). We have success-
fully established lymphoblastoid cell lines
that synthesize antibody directed against
a human tumour-associated foetal antigen
(TAFA) designated as Oncofoetal Antigen-
I (OFA-I).
OFA-I, first described by our laboratory
(Irie et al., 1976), is a membrane antigen
on various histological types of human
cancer cells that cross-reacts with human
foetal brain tissue, but has not been found
in foetal liver, spleen, and thymus, or on
any normal adult cells. OFA-I has been
shown to be immunogenic in man, by its
ability to provoke humoral antibody in
patients with cancer using indirect mem-
brane immunofluorescence (IMIF) (Irie
et al., 1976) and immune-adherence (IA)
(Irie et al., 1976, 1979b). Recentlywe repor-
ted that the disease-free interval of post-
operative Stage II melanoma patients
strongly correlates with their serum level
of IgM anti-OFA-I (Jones et al., 1981).
This fact, coupled with the finding that
serum anti-OFA-I is cytotoxic in the
presence of either rabbit or human com-
plement to OFA-I+ tumour cells (Sidell
et al., 1979a, b), suggests that IgM anti-
OFA-I could confer some protection
against tumour growth in vivo. The ability
to produce IgM anti-OFA-I in vitro as
described in this report should enable us
to define more precisely the role of this
TAFA in human cancer.
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Ten serum samples containing high
levels of anti-OFA-I antibody were first
identified from more than 5000 serum
samples that had been tested for anti-
OFA-J specificity by IA or IMIF (Irie
et al., 1976, 1979a; Jones et al., 1981) by
the dates of acquisition. Viably frozen
peripheral-blood lymphocytes (PBL) to be
transformed by EB virus were then
matched to these 10 sera from the same
individuals. The patient population in this
study included 5 who received adjuvant
immunotherapy with an OFA-I+ tumour-
cell vaccine (TCV), 3 who had been treated
with BCG immunotherapy, and 2 who had
had surgical excision but no adjuvant
therapy. EB virus from the spent tissue-
culture medium of B-95-8 marmoset
lymphoblastoid cells was used to trans-
form 2 x 106 of the chosen PBL, as pre-
viously described (Irie et al., 1976; Miller
& Lipmen, 1973). Halfthe medium (RPMI
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with 100% foetal calf serum) was changed
every 3rd day in each culture, and the
volume was adjusted so that cell numbers
were maintained at 2 x 105 cells/ml. Anti-
OFA-J levels in the spent medium of each
culture were monitored by IA using an
OFA-I+ melanoma cell line, UCLA-SO-
M14 (M14), as the target cell. Each pro-
cedure has been described (Irie et al.,
1976, 1979b). Theantibodytitre wasdefined
as the reciprocal dilution at which 50°/0 of
M14 target cells were involved in rosette
formation with the human erythrocyte
indicator cells (IA50). Reactivity to UCLA-
SO-L14 (L14), a lymphoblastoid cell line
autologous to the M14 donor, was also
examined as an alloreactivity control
(Saxton et al., 1978; Pellegrino etal., 1977).
As shown in the figure, 2 of the
EBV-infected cultures (ES from the TCV
group and CD from the surgery-only
group) produced detectable antibody to
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FIGURE. Antibody titre to OFA-I+ M14 melanoma7target cells. Antibody was derived from culture
medium of EBV-transformed PBL from selected melanoma patients with high titres of circulating
IgM antibody to OFA-I. Parenthesis indicates the titre ofcirculating antibody to OFA-1 in serafrom
patients on the day the PBL were obtained. Of 10 patients' PBL tested, 7 lines (LE-O (128), L-MR
(512), L-RB (512), L-GA (1024), L-AO (1024), L-OJ (2048), and L-DP (2048)) produced no detect-
able anti-OFA-I antibody during 60 days observation, though cells were established as permanent
lines.
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M14 melanoma cells by Day 6. By Day 9,
another transformed PBL culture, DV
(BCG group), became positive. The CD
culture only remained positive until Day
9. The ES culture, obtained from the
patient with the highest titre ofcirculating
anti-OFA-1 antibody (1: 4096), ceased
growing after 3 weeks. Supernatants from
these 3linesdisplayedno antibodyactivity
TABLE I.-Absorption of anti-M14 anti-
body reactivityfrom spent culture medium
ofDV lymphoblastoid cell line by OFA-I+
or OFA-I tissues
OFA-I ex- IA50 after
Tissues used for absorption pression* absorption
Biopsied or necropsied human
tissues (100,l tissue/100 1l
spent medium)
2nd trimester foetal brain + + <1
2nd trimestar foetal liver - 16-32
Melanoma (GW, subcutaneous
metastasis) + + <1
Melanoma (AK, lymph-node
metastasis) + + <1
Melanoma (MM, primary,
subcutaneous) + 8
Melanoma (CB, lung
metastasis) + 8
Melanoma (SN, spleen
metastasis) - 32
Skin (AK) - 32
Skin (CB) - 16-32
Skin (MM) - 32
Spleen (SN) - 32
Cultured human tissuest
(cells/100,l spent medium)
UCLA-SO-M14 melanoma
(2x106) ++ <1
L14 lymphoblasts (2 x 107) - 32
M7 melanoma (2 x 106) + + <1
M10 melanoma (2 x 106) + + <1
L10lymphoblasts (2 x 107) - 32
M18 melanoma (2 x 106) + + <1
LI8 lymphoblasts (2 x 107) - 32
M15 melanoma (2 x 106) - 32
L15 lymphoblasts (2 x 107) - 32
M25 melanoma (2 x 106) + 8
A+, B+, AB+ human
erythrocytes (2 x 108) - 32
Sheep erythrocytes (2 x 108) - 32
Bovine erythrocytes (2 x 108) - 32
Mouse erythrocytes (2 x 108) _ 16-32
Antibody not absorbed 32
* OFA-I expression on these tissues had been
confirmed in our previous study (Irie et al., 1976).
t M14 and L14, M1O and LIO, M18 and L18, and
M15 and L15 were derived from same individuals,
respectively, and shown to express identical HLA
antigens (Pellegrino et al., 1977).
to L14. The DV lymphoblasts continued
to produce increasing titres of anti-M14
antibody until Day 42, when the titre was
1: 32. This titre lasted for 6 days, gradually
decreased to 1: 8 by Day 60, and became
negative on Day 66. None of the other 7
PBL culture supernatants became positive
toM14.
The specificity of the antibody to the
Ml4 melanoma cells in the DV spent
medium was determined by absorption
techniques (Irie et al., 1976) (Table I).
Absorption of supernatant with the L14
lymphoblasts did not decrease the anti-
body titre, confirming that the M14 reac-
tivity was not due to antibody directed
against HLA specificities (Saxton et al.,
1978; Pellegrino et al., 1977). However,
peak anti-MI4 reactivity (1: 32 titre) could
be completely abolished by absorption
with OFA-I+ second-trimester human
foetal brain tissue. Foetal liver tissue
from the same foetus did not significantly
reduce the antibody titre, indicating that
the activity to M14 was due to anti-OFA-I
(Irie et al., 1976). This specificity was
confirmed by absorption with a series of
other OFA-I+ and OFA-1- tissues (Table
TABLE II.-Reactivity of anti-OFA-I con-
taining DV spent medium* to M14
cells by indirect membrane immuno-
fluoretcence
FITC-labelled antibody
used for detectiont
Goat anti-human IgM
(,u-chain specific)
Goat anti-human IgG
(y-chain specific)
Goat anti-human IgA
(y-chain specific)
Goat anti-bovine
immunoglobulin
Fluoresceinated cells
in 100 counted
Concentration of
spent medium
A
lOx I x
82 14
0 0
0 0
0 0
* DV spent medium was tested after 10-fold con-
centration by 50% ammonium sulphate precipita-
tion.
t Positive controls for each FITC-labelled anti-
body included IgM, IgG, and IgA anti-M14 obtained
from cancer patients immunized with the M14 cell
line (Irie et al., 1979a).
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I). These findings represent the first report
of in vitro synthesized human antibody
with specific reactivity to an antigen asso-
ciated with human cancer. To ascertain
whether the DV lymphoblasts produced
antibody with other specificities, such as
allo or heterologous antibodies, the spent
medium was tested against various allo-
geneic and xenogeneic target cells, includ-
ing 16 different human lymphoblastoid
cell lines (2 T-cell lines and 14 B-cell lines),
PBL from 5 donors, human erythrocytes
from 20 donors, sheep erythrocytes (Forss-
manantigen-positive), bovineerythrocytes
(Paul-Bunnell, Serum Sickness and Fede-
roff antigen-positive) and mouse erythro-
cytes (Federoff and Forssman antigen-
positive). No antibody reactivity in the
DV culture medium was detected to any
of these target cells, using a variety of
serological assay techniques, including
IA, haemagglutination, and immune
haemolysis (data not shown).
An assessment of the immunoglobulin
class produced in the DV culture was
accomplished by using FITC-labelled
monospecific goat antihuman IgG (y-chain
specific), antihuman IgM (p-chainspecific),
or antihuman IgA (y-chain specific) as the
second antibody in the IMIF, assay as
described in Irie et al. (1979). As indicated
in Table II, more than 80% of the anti-
body-coated M14 target cells were stained
by the goat antihuman IgM, while no cells
were stained by antibodies to human IgG
or IgA. Thus the anti-OFA-1 produced in
this culture was apparently limited to the
IgM class. This finding was consistent with
the in vivo situation ofdonor DV, in whom
only circulating IgM anti-OFA-1 was
detected. Negative results using FITC-
labelled goat antibovine polyvalent Ig as
the second antibodyfurther confirmedthat
all the reactivity against M14 was due to
human antibody and not to heterophile
antibodies in the bovine serum used to
supplement the DV lymphoblast culture
medium.
Crucial for any further immunothera-
peutic applications of in vitro-produced
anti-OFA-1 is the need for these antibodies
TABLE III.-Complement-dependent cyto-
toxicity* of anti-OFA-I containing DV
spent medium
% Specific 51Cr releaset
Concentration of spent medium
Target cells
M14 (OFA-I+
melanoma)
M15 (OFA-I-
melanoma)
L14§ (OFA-I-
lymphoblasts)
lOx 1/2 1/4
87 (41)t 43 (21) 17 (10)
0 1 3
2 0 2
* Assessed after 1-5h incubation at 37°C of 51Cr-
labelled target cells (104 cells in 50 ,ul of medium)
with an equal volume of supernatant at the dilution
indicated, and complement (rabbit serum diluted
1:4).
t % Specific release=
% release with antibody
and complement - % spontaneous release
00 maximum release - % spontaneous release
Maximum release was 92% by detergent lysis;
spontaneous release was taken as the values from
the tubes containing complement alone and was
always < 11% for M14 and M15, and < 20% for L14.
Additional controls included tubes containing heat-
inactivated complement and spent medium, and
spent medium alone, which were always less than
the complement controls.
t Numbers in parentheses indicate the specific
release in the presence of human complement
(human serum diluted 1:3). Fresh human AB serum
was treated by M14 at 0°C to remove natural anti-
body to M14 cells, and used as a complement source.
§ Derived from PBL of M14 donor.
to be cytotoxic. As such, we tested the
cytotoxic activity of the antibody in the
DV spent medium against M14 cells when
the IA titre was 1: 32. Results ofthe 5lCr-
release assay (Sidell et al., 1979b) demon-
strated that the in vitro-produced anti-
OFA-J, like serum anti-OFA-I, was cyto-
toxic in the presence of either rabbit or
human complement (Table III). No cyto-
toxicity was observed against OFA-1-
M15 melanoma and L14 cells.
We concluded that the antibody pro-
duced by the DV lymphoblasts was of the
IgM class, was monospecific for OFA-I
(though not necessarily monoclonal) and
could effectively lyse tumour cells express-
ing this antigen. The decrease of anti-M14
reactivity in the culture supernatants with
time was frustrating. The same pheno-
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menon was also reported with tetanus
antitoxin and diphtheria antitoxin pro-
duced by EBV-induced lymphoblastoid
cell lines (Zurawski et al., 1978; Tsuchiya
et al., 1980). Further efforts are now under
way to establish lymphoblastoid cell lines
that will permanently produce anti-OFA-
I, as well as to isolate highly active sub-
clones from the DV lymphoblastoid cells
which were cryopreserved at the time of
peak antibody reactivity. These early-
passage cell cultures demonstrate anti-
OFA-J titres of 1: 16-32 within 3 days of
thawing. In any case, the ease of estab-
lishing anti-OFA-1-producing lymphoblas-
toid cell lines from the PBL of patients
with high titres of circulating anti-OFA-1
should allow us to obtain ample amounts
of homogeneous antibody for further
characterization of the OFA-J antigen-
antibody system.
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